

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)


PCT

(10) International Publication Number  
**WO 2004/026234 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number:  
PCT/US2003/028964
- (22) International Filing Date:  
19 September 2003 (19.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/319,563 19 September 2002 (19.09.2002) US  
10/605,283 19 September 2003 (19.09.2003) US
- (71) Applicant: UNIVERSITY OF SOUTH FLORIDA  
[US/US]; 4202 East Fowler Avenue, FAO 126, Tampa, FL  
33620-7900 (US).
- (72) Inventors: BHALLA, Kapil, N.; 12902 Magnolia Drive,  
MRC-3E 3056D, Tampa, FL 33612 (US). NIMMANA-  
PALLI, Ramedevi; 12902 Magnolia Drive, MRC-3E  
3056D, Tampa, FL 33612 (US).
- (74) Agent: HOPEN, Anton, J.; Smith & Hopen, P.A., Suite  
220, 15950 Bay Vista Drive, Clearwater, FL 33760 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: METHOD OF TREATING LEUKEMIA WITH A COMBINATION OF SUBEROYLANILIDE HYDROMAXIC ACID AND IMATINIB MESYLATE



(57) Abstract: A method for inducing apoptosis, or increasing the rate or extent of apoptosis, in target cells. The method comprises the steps of contacting the cancer cells with an apoptosis-inducing amount of a tyrosine kinase inhibitor, imatinib mesylate, and a histone deacetylase inhibitor, Suberoylanilide Hydromaxic Acid (SAHA). The method is applicable to ameliorating the resistance of the accelerated and blast phases of CML (CML-BC) to imatinib mesylate.



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

## Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate

### Cross-Reference to Related Applications

This application claims priority to U.S. Application Serial No. 10,605,283, also entitled: "Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate," filed September 19, 2003, which claims benefit of U.S. provisional application Serial No. 60/319,563, entitled: "Suberoylanilide Hydroxamic Acid Treatment of Leukemia Cells", filed September 19, 2002.

### Field of Invention

This invention relates to a treatment for leukemia. More specifically, the invention is a method for increasing the extent or rate of apoptosis in a subject, particularly in association with leukemia therapy protocols.

### Background of Invention

Apoptosis, also called programmed-cell-death, is a normal process by which cells self-destruct. Apoptosis, when properly regulated, is a beneficial process by which cells disintegrate into compact units which are then phagocytized by neighboring cells. Apoptosis can be triggered by a loss of contact with neighboring cells, smothering of the cell surface, or DNA damage. Once triggered, the process includes the contraction and concentration of the cytoplasm, chromatin condensation and pyknosis, and segmentation of the nucleus. The DNA in the nucleus degrades into nucleosomal fragments coupled with cellular fission resulting in the formation of apoptic bodies. The cellular fragments are "eaten," phagocytized, by neighboring cells. This process is a method of protection for cells that are malfunctioning. In particular, induction of apoptosis is beneficial if the process causes the death of abnormal cells, such as cancer cells.

Resistant forms of cancer have acquired the ability to avoid at least some triggers of apoptosis. Downregulation of apoptosis is involved in a number of diseases and conditions, particularly leukemia. By gaining control of apoptotic pathways, it is possible to diminish the occurrence of cancerous cells in a subject.

Studies have shown that 95% of all chronic myeloid leukemia (CML) and 20% of adult acute lymphoblastic leukemia cases bear the Bcr-Abl fusion oncogene. The oncogene creates the Bcr-Abl protein. The Bcl proteins are associated with membrane activity and play a vital role in signaling and controlling apoptosis. As a result the overexpression of this protein can prevent apoptosis in damaged cells in which apoptosis would otherwise be triggered. Bcr-Abl positive cells are specifically resistant to apoptosis induced by DNA damage. It is known that dysregulated activity of the Bcr-Abl tyrosine kinase in the cytosol activates several molecular mechanisms that inhibit apoptosis, and as a result contribute to the drug-resistance of Bcr-Abl positive leukemia blasts.

The advent of imatinib mesylate brought about great step in the fight against leukemia. Imatinib mesylate is a selective inhibitor of the Bcr-Abl tyrosine kinase. Imatinib mesylate works to bind the Bcr-Abl receptors thereby blocking adenosine triphosphate (ATP) binding. The Bcr-Abl protein cannot carry on its kinase activity without the energy supplied by the ATP molecule.

Imatinib mesylate has shown impressive results in selectively inducing apoptosis in chronic phase CML, however the accelerated and blast phases of CML (CML-BC) have shown to be resistant to imatinib mesylate. Therefore, a need exists to identify additional agents that work with imatinib mesylate, or alone, to increase the rate or extent of apoptosis in target living cells.

#### Summary of Invention

It has been discovered that the rate or extent apoptosis can be induced in living cells by contacting the target cells with an apoptosis-inducing amount of a tyrosine kinase inhibitor and a histone deacetylase inhibitor that:

- a. inhibits the binding of ATP with the BCR-ABL protein, thus preventing the Bcr-Abl protein from carrying out its kinase activity;
- b. induces hyper-acetylation of the amino terminal lysine residues of the core nucleosomal histones and of specific transcriptional regulators.

In another embodiment the invention relates to a method of ameliorating the resistance of the accelerated and blast phases of CML (CML-BC) to imatinib mesylate, comprising the steps of administering to the subject a combination tyrosine kinase inhibitors and histone deacetylase inhibitors in an amount effective to

selectively accumulate in target cells and contacting the target cells with an apoptosis-inducing amount of a tyrosine kinase inhibitor and a histone deacetylase inhibitor.

Treatment with the tyrosine kinase inhibitor imatinib mesylate (GLEEVEC, formerly known as STI571 or CGP57148B) has been shown to selectively inhibit the growth of, and induce apoptosis in, leukemia cells that possess Bcr-Abl tyrosine kinase activity. Although treatment with imatinib mesylate alone has been successful with cells in the chronic phase, the accelerated and blast crisis phases of chronic myeloid leukemia (CML-BC) and Bcr-Abl positive acute lymphoblastic leukemia (ALL) prove to be highly resistant to imatinib mesylate. However, CML cells exposed to concentrations of (1.0  $\mu$ M to 10.0  $\mu$ M) of the histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) and imatinib mesylate for 48 hours drastically increased apoptosis, on a dose dependant basis, in CML and imatinib mesylate-refractory (CML-BC) cells.

#### Brief Description of Drawings

For a fuller understanding of the nature and objects of the invention, reference should be made to the following detailed description, taken in connection with the accompanying drawings, in which:

Figure 1 is a diagrammatic view of the method according to the invention.

Figure 2 shows levels of apoptosis after exposure to SAHA, in the indicated concentrations for 48 hours.

Figure 3 shows results of co-treatment of SAHA and imatinib mesylate, in indicated concentrations, for 48 hours (Figures 3A – 3C) and 24 hours (Figure 3D).

#### Detailed Description

An embodiment of the invention includes detecting and identifying target leukemia cells within a patient. Turning to Fig. 1, cells are diagnosed and treatment is administered comprising of a combination of imatinib mesylate and SAHA substantially concurrently 20. Once administered imatinib mesylate causes apoptosis in chronic phase CML cells via known pathways 30. Concurrently, SAHA inhibits the activity of histone deacetylases in imatinib refractory cells, resulting in apoptosis 40. The percentage of apoptic cells can then be determined by flow cytometry 50, wherein samples of mononuclear cells are passed through a beam of laser light. On a result-dependent basis the dosage can be adjusted 60 and re-administered 20, the

dosage can be adjusted on either an increased concentration or increased exposure basis. If satisfactory results are achieved treatment is discontinued pending further detection or increase in CML cell activity 70.

SAHA is a known histone deacetylase (HDAC) inhibitor. HDAC inhibitors induce hyper-acetylation of the amino terminal lysine residues of the core nucleosomal histones and of specific transcriptional regulators. Such activity has been implicated in chromatin remodeling and transcriptional upregulation of cell-cycle and differential regulatory genes, such as p21, thus resulting in apoptosis, cell death, of cancer and leukemia cells.

With regard to the treatment of leukemia, the Bcl-Abl protein is of particular interest. Bcl-2 (B cell lymphoma gene-2) proteins are associated with membrane activity and play a key role in controlling, or preventing, apoptosis. The overexpression of this protein can prevent apoptosis in damaged cells, such as leukemia cells, and increase the cells resistance to treatments such as imatinib mesylate.

Imatinib mesylate is a tyrosine kinase inhibitor. Imatinib mesylate works to induce apoptosis in cancerous cells by binding to the malfunctioning Bcr-Abl receptors and blocking ATP. Thus Bcr-Abl cannot continue to perform thus inducing apoptosis. Although imatinib mesylate has shown impressive results in selectively inducing apoptosis in chronic phase CML, the accelerated and blast phases of CML (CML-BC) have shown to be resistant to imatinib mesylate.

Target cell exposure to 1.0 to 10.0  $\mu$ M SAHA for 48 hours induces a dose-dependent increase in the apoptosis of K562 and Lama-84 cells (Fig. 2A). Treatment with 1.0 to 5.0  $\mu$ M SAHA for 48 hours increased the percentage of K562 in the G1 (the gap in the cell division cycle between mitosis and synthesis) phase of the cell cycle in a dose-dependent manner.

Moreover, exposure to SAHA increases the acetylation of histones (H3) and the expression of p21 (Fig. 2B). Treatment with SAHA induced p27 expression concurrently in both K562 and LAMA cells (Fig. 2B). Previously, SAHA had been shown not to induce acetylation of histones of the chromatin associated with p27(gene) or increase its transcription. SAHA downregulates the levels and auto-phosphorylation, the addition of a phosphate group, of Bcr-Abl (Fig. 2C).

Combined treatment with SAHA and imatinib mesylate for 48 hours induced more apoptosis of target cells as compared to the treatment with either agent alone as shown in Figs. 3A and 3B. This increase in apoptotic effect is associated with an increased decline in the levels of Bcr-Abl, p-Akt and procaspase 3 (Fig. 2C). Effectiveness of the combination of the agents was effective on an exposure-dependent, shorter exposures to the combination induced a lesser apoptotic effect.

Therefore, treatment of leukemia by combining exposure of the target cells to SAHA and imatinib mesylate, concurrently, clearly shows that the downregulation of Bcr-Abl, caused by SAHA, induces apoptosis in imatinib refractory (resistant) cells. Collectively, combined treatment with SAHA and imatinib mesylate against the advanced stages of CML, in addition to the effects of SAHA on imatinib refractory CML-BC, is a superior method for the treatment of leukemia.

The pharmaceutical composition of the invention may also comprise a pharmaceutically acceptable carrier, methods of formulation are well-known in the art. Accordingly, the invention includes a chemical composition for inducing apoptosis in cancer cells including a tyrosine kinase inhibitor, imatinib mesylate, and a histone deacetylase inhibitor, SAHA. This invention provides a method of treating living cells, which include, but is not limited to, humans and other mammals. Factors such as the method of administration, the patient's age, severity of the disease, and similar variables are to be considered when deciding on a subject-specific dosage.

It will be seen that the objects set forth above, and those made apparent from the foregoing description, are efficiently attained and since certain changes may be made in the above construction without departing from the scope of the invention, it is intended that all matters contained in the foregoing description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense. It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described, and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween. Now that the invention has been described,

What is claimed is:

1. A method for inducing apoptosis in cancer cells, the method comprising the steps of contacting the living cells with a tyrosine kinase inhibitor and a histone deacetylase inhibitor.
2. The method of claim 1 wherein the tyrosine kinase inhibitor is imatinib mesylate.
3. The method of claim 1 wherein the histone deacetylase inhibitor is suberoylanilide hydroxamic acid.
4. The method of claim 1 wherein the tyrosine kinase inhibitor is imatinib mesylate and the histone deacetylase inhibitor is suberoylanilide hydroxamic acid.
5. Method of claim 1 wherein the living cells are exposed to the tyrosine kinase inhibitor and the histone deacetylase inhibitor for about 48 hours.
6. Method of claim 1 wherein the cancer cells are leukemia cells.
7. Method of claim 1 wherein the cancer cells are imatinib mesylate refractory.
8. A method of potentiating a cytotoxic effect of a tyrosine kinase inhibitor-based treatment comprising the steps of contacting target cells with a histone deacetylase.
9. The method of claim 8 wherein the tyrosine kinase inhibitor-based treatment comprises imatinib mesylate.
10. The method of claim 8 wherein the histone deacetylase inhibitor is suberoylanilide hydroxamic acid.
11. Method of claim 8 wherein the target cells are leukemia cells.
12. Method of claim 8 wherein the target cells are imatinib mesylate refractory.
13. A chemical composition for inducing apoptosis in cancer cells comprising a tyrosine kinase inhibitor and a histone deacetylase inhibitor.
14. The chemical composition of claim 13 wherein the tyrosine kinase inhibitor is imatinib mesylate.
15. The chemical composition of claim 13 wherein the histone deacetylase inhibitor is suberoylanilide hydroxamic acid.



16. The chemical composition of claim 13 wherein the tyrosine kinase inhibitor is imatinib mesylate and the histone deacetylase inhibitor is suberoylanilide hydroxamic acid.

Fig. 1






Fig. 2

A.



B.



C.





Fig. 3



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number  
**WO 2004/026234 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/505**,  
31/675

(21) International Application Number:  
PCT/US2003/028964

(22) International Filing Date:  
19 September 2003 (19.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/319,563 19 September 2002 (19.09.2002) US  
10/605,283 19 September 2003 (19.09.2003) US

(71) Applicant: **UNIVERSITY OF SOUTH FLORIDA**  
[US/US]; 4202 East Fowler Avenue, FAO 126, Tampa, FL  
33620-7900 (US).

(72) Inventors: **BHALLA, Kapil, N.**; 12902 Magnolia Drive,  
MRC-3E 3056D, Tampa, FL 33612 (US). **NIMMANA-**  
**PALLI, Ramedevi**; 12902 Magnolia Drive, MRC-3E  
3056D, Tampa, FL 33612 (US).

(74) Agent: **HOPEN, Anton, J.**; Smith & Hopen, P.A., Suite  
220, 15950 Bay Vista Drive, Clearwater, FL 33760 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

(88) Date of publication of the international search report:  
8 July 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



WO 2004/026234 A3

(54) Title: **METHOD OF TREATING LEUKEMIA WITH A COMBINATION OF SUBEROYLANILIDE HYDROMAXIC ACID  
AND IMATINIB MESYLATE**

(57) Abstract: A method for inducing apoptosis, or increasing the rate or extent of apoptosis, in target cells. The method comprises the steps of contacting the cancer cells with an apoptosis-inducing amount of a tyrosine kinase inhibitor, imatinib mesylate, and a histone deacetylase inhibitor, Suberoylanilide Hydromaxic Acid (SAHA). The method is applicable to ameliorating the resistance of the accelerated and blast phases of CML (CML-BC) to imatinib mesylate.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/28964

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/505, 31/675  
US CL : 514/274, 252.18, 253.01, 86, 88, 908

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 514/274, 252.18, 253.01, 86, 88, 908

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| A, P       | US 6,645,972 B2 (JOLIVET et al.) 11 November 2003 (11.11.2003) see entire document  | 1-16                  |
| Y          | Martinelli et al. Molecular therapy for multiple myeloma, Haematologica September 2001; Vol. 86 No. 9 pages 908-917, see abstract | 1-16                  |
| Y, P       | US 2003/0166557 A1 (MINNA et al.) 04 September 2003 (04.09.2003), see entire document.  | 1-16                  |

Further documents are listed in the continuation of Box C.

See patent family annex.

| * Special categories of cited documents:  | "T"  |
|---|--|
| "A" document defining the general state of the art which is not considered to be of particular relevance  | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| "B" earlier application or patent published on or after the international filing date   | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" document referring to an oral disclosure, use, exhibition or other means  | "&" document member of the same patent family  |
| "P" document published prior to the international filing date but later than the priority date claimed  |  |

Date of the actual completion of the international search

Date of mailing of the international search report

09 February 2004 (09.02.2004)

14 APR 2004

Name and mailing address of the ISA/US

Authorized officer

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Donna Jagoe

Facsimile No. (703) 305-3230

Telephone No. (571) 272-0600

Form PCT/ISA/210 (second sheet) (July 1998)